Blog

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

Naveen Pemmaraju/mdanderson.org

Apr 29, 2025, 09:33

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared an article by Naval Daver, et al. on X:

“Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis | Led by Naval Daver and Hussein Abbas.”

Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis.

Journal: Clinical Cancer Research.

Authors: Naval Daver, et al.

Naveen Pemmaraju: Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed AML

More posts featuring Naveen Pemmaraju.

AML azacitidine BPDCN Program cancer fight against cancer Global fight against cancer Hussein Abbas magrolimab MD Anderson Cancer Center Naval Daver Naveen Pemmaraju OncoDaily Oncology University of Texas venetoclax

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers

Top 5 AI Tools for Radiation Oncologists: What Clinicians Need to Know